Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Uterine Cancer

Sponsor
Case Comprehensive Cancer Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03583736
Collaborator
(none)
0
2
23.2

Study Details

Study Description

Brief Summary

This project aims to evaluate whether rapid first contact with the oncologist the same day or the next day after pathologic diagnosis contributes to a decreased time to treatment, decreased patient anxiety and increased patient satisfaction.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Virtual visit
  • Behavioral: Office visit
N/A

Detailed Description

Time to treatment (time from disease diagnosis to initiation of treatment) impacts outcomes in uterine cancer. When controlled for stage, patients with longer time to treatment tend to have less favorable outcomes. Similarly, longer time to treatment has a negative impact on patients' quality of life and markers for anxiety. Our experience at this institution suggests that the time to referral (time from uterine cancer diagnosis and the patients' first encounter with the oncologist) is variable and presents the greatest opportunity for decreasing time to treatment. Among the factors that contribute to the time to referral are the time taken by the referring provider to relay the diagnosis to the patient, time taken to schedule an appointment with the specialist, and the patient's availability to keep an appointment.

Virtual visits provide an opportunity to expedite consultation with the treating oncologist by removing some of the barriers that delay face-to-face visits. Among these barriers are patients' availability for a short notice face-to-face visit based on their work or family obligations, access to transportation, and mental preparedness.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Patients With Uterine Cancer
Actual Study Start Date :
Jun 27, 2018
Anticipated Primary Completion Date :
Jun 1, 2020
Anticipated Study Completion Date :
Jun 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Rapid first contact virtual visit

Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.

Behavioral: Virtual visit
Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.

Placebo Comparator: First contact in person office visit

Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.

Behavioral: Office visit
Scheduled office visit with oncologist following uterine cancer diagnosis.

Outcome Measures

Primary Outcome Measures

  1. Time to treatment following diagnosis to treatment initiation [30 days]

    How long between diagnosis to treatment

Secondary Outcome Measures

  1. Amount of anxiety demonstrated when virtual visits are added [30 days]

    Level of anxiety using GAD-7

  2. Number of patients willing to pay for a virtual visit [30 days]

    Assess patients valuation of virtual visits by measuring their willingness to pay

  3. Number of patients with improved satisfaction scores [30 days]

    Determine whether the addition of a rapid virtual visit improves patients satisfaction

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Uterine cancer diagnosis on biopsy read by Cleveland Clinic Pathology Department

  • Patients must be willing to participate in a virtual visit as the initial meeting with an oncologist at the Cleveland Clinic.

  • Receive care at Fairview Hospital, Hillcrest Hospital or Cleveland Clinic Main Campus

  • Internet connected smartphone or internet connected computer with webcam

  • Participants must have email access

  • English speaking

  • Competent to make clinic decisions

Exclusion Criteria:
  • No diagnosis of uterine cancer

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Case Comprehensive Cancer Center

Investigators

  • Principal Investigator: Jason Knight, MD, Cleveland Clinic, Case Comprehensive Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT03583736
Other Study ID Numbers:
  • CASE3818
First Posted:
Jul 11, 2018
Last Update Posted:
Jun 30, 2020
Last Verified:
Jun 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 30, 2020